Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Jul 27, 2025; 17(7): 106487
Published online Jul 27, 2025. doi: 10.4240/wjgs.v17.i7.106487
Baohe Pingwei power plus neoadjuvant chemotherapy for gastric cancer
Hong-Yu Ma, Xin Liu, Yuan-Wu Chen, Jing Liang, Jie Wang, Ming-Ming Zhang, Qian Yang
Hong-Yu Ma, Jie Wang, Qian Yang, Department of Spleen and Stomach Diseases, First Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang 050011, Hebei Province, China
Hong-Yu Ma, Department of Traditional Chinese Medicine, Hebei General Hospital, Shijiazhuang 050011, Hebei Province, China
Xin Liu, Graduate School of Hebei Medical University, Shijiazhuang 050017, Hebei Province, China
Xin Liu, Ming-Ming Zhang, Clinical Medicine Research Center, Hebei General Hospital, Shijiazhuang 050011, Hebei Province, China
Xin Liu, Hebei Key Laboratory of Metabolic Diseases, Hebei General Hospital, Shijiazhuang 050011, Hebei Province, China
Yuan-Wu Chen, Department of Rehabilitation, Hebei General Hospital, Shijiazhuang 050011, Hebei Province, China
Jing Liang, Guang’anmen Hospital South Campus, China Academy of Chinese Medical Sciences, Beijing 102600, China
Qian Yang, Hebei Key Laboratory of Turbidity Toxin Syndrome, Shijiazhuang 050011, Hebei Province, China
Co-corresponding authors: Ming-Ming Zhang and Qian Yang.
Author contributions: Ma HY designed the research; Liu X performed the research; Chen YW, Liang J, and Wang J contributed new reagents or analytical tools; Ma HY analyzed the data; Ma HY and Wang J wrote the paper; The designation of Yang Q and Zhang MM as co-corresponding authors is justified by their equal and complementary contributions to the study; Yang Q, as Head Doctor of the Department of Spleen and Stomach Diseases, provided critical clinical expertise and oversight in patient management, particularly in integrating traditional Chinese medicine with modern therapeutic approaches Zhang MM from the Clinical Medicine Research Center contributed essential methodological rigor, experimental design, and data analysis, ensuring the study’s scientific validity; Their collaboration bridged traditional Chinese medicine theory and contemporary research standards, enhancing the study’s interdisciplinary impact. Additionally, by representing two key institutions (the First Affiliated Hospital of Hebei University of Chinese Medicine and Hebei General Hospital), their joint leadership underscored the multicenter nature of the research, bolstering its credibility and applicability; Both authors also shared responsibilities in ethical oversight, communication with stakeholders, and manuscript dissemination, reflecting their shared accountability for the study’s integrity and success; This dual correspondence acknowledges their synergistic roles in guiding the project to completion; All authors read and approved the final manuscript.
Supported by Scientific Research Project of Hebei Administration of Traditional Chinese Medicine, No. 2025271; the Construction Project of National Clinical Research Base of Traditional Chinese Medicine, Science Letter[2018], No. 131; Natural Science Foundation of Hebei Province, No. H2023423001; Key Research Project of the Ministry of Science and Technology, No. 2018YFC1704100 and No. 2018YFC1704102; Provincial Science and Technology Program of Hebei Province, No. 21377724D and No. 21377740D; Scientific Research Project of Hebei Administration of Traditional Chinese Medicine, No. 2021034, No. 2022026, No. 2022032, and No. 2023022; and Medical Science Research Project of Hebei Province, No. 20190756.
Institutional review board statement: The study was reviewed and approved by the Harbin Medical University Cancer Hospital Institutional Review Board.
Informed consent statement: All subjects understood and agreed to the study protocol and voluntarily signed the informed consent form.
Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qian Yang, Chief Physician, Department of Spleen and Stomach Diseases, First Affiliated Hospital of Hebei University of Chinese Medicine, No. 389 Zhongshan East Road, Shijiazhuang 050011, Hebei Province, China. yang0311qian@126.com
Received: March 5, 2025
Revised: March 25, 2025
Accepted: April 18, 2025
Published online: July 27, 2025
Processing time: 140 Days and 4.2 Hours
Core Tip

Core Tip: Baohe Pingwei powder when combined with neoadjuvant chemotherapy exhibited significant efficacy in postoperative patients with gastric cancer. This study revealed that the addition of Baohe Pingwei powder enhanced treatment outcomes, improved immune function, and reduced adverse reactions compared with chemotherapy alone. The most innovative finding was the ability of the powder to prolong recurrence-free survival, highlighting its potential as an adjuvant therapy for patients with gastric cancer undergoing surgery.